Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
January 13, 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…